D
Dr Reddys Laboratories Ltd
Pharmaceuticals
₹ 1,292.10 -7.70 (-0.59%)
₹ 1,292.10 -7.70 (-0.59%)
- NSE
- BSE
Overview
- BSE Code 500124
- NSE Symbol DRREDDY
- ISIN Demat INE089A01031
- Book Value (₹) 345.76
- Face Value (₹) 1.00
- Market Cap (₹ Cr.) 1,04,998.73
- P/E (TTM) 19.51
- EPS (TTM) 64.48
- Div Yield (%) 0.64
Performance
Today’s Low 1,277.70
Today’s High 1,298.10
52W Low 1,020.00
52W High 1,421.49
Open 1,298.10
Prev. Close 1,299.80
Volume 19,43,466.00
Corporate Actions
Dr. Reddy's Laboratories Limited - Press Release
Apr 24, 2025Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated April 24, 2025, titled "Intimation of Earnings call".
About Dr Reddys Laboratories Ltd
History
Dr Reddy's Laboratories came into existence as in 1984 in Hyderabad. It was established by Dr Anji Reddy with an initial capital outlay of ₹25 lakh. Mr. Reddy was one of the pioneers of the active pharmaceutical ingredients or APIs industry in India. Before establishing Dr. Reddy’s Laboratories, he had already co-founded two bulk drug manufacturing ventures. The company made its beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (APIs) and commenced operations with a single drug in a 60-tonne facility near Hyderabad. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Thereafter, they made a strategic entry into the international market with exports of Methyldopa. In the year 1987, the company obtained the first USFDA approval for Ibuprofen API. In 1991, the company began production of Omeprazole, which is one of its most popular drugs. In 1993, the Dr. Reddy’s Research Foundation was established, which core priorityed on drug discovery, especially for cancer and diabetes. In 1998, they started their biologics business to offer affordable medicine to the Indian consumer. In 2003, the company launched its first generic product, i.e. Ibuprofen, under their label in the US. In 2019, the company made a strategic entry into the nutrition segment in India through the launch of Celevida.Business Segments
Dr. Reddy's offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company core priorityes on areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's is today a global company with a strong presence abroad. Its major markets include - the USA, India, Russia, and Europe. The company has primarily 3 businesses:- Pharmaceutical services and active ingredients production - This is the largest source of revenue for the company, bringing in roughly 83% of the revenue in FY 2022. As of September 2023, the company delivers 400+ generic drugs at affordable costs by leveraging its integrated operations. Drugs related to the nervous system bring in the most revenue.
- Global generic drug production - Dr. Reddy’s Laboratories works on API development to help its own generic drugs enterprise become cheaper as well as to launch products in the market faster than its competitors.
- Proprietary Products - This mostly involves the organization developing various formulas to enhance efficiency and ease of use, among other factors.
Key Personnel
Erez Israeli, CEO Erez Israeli is the Chief Executive Officer of Dr. Reddy’s Laboratories. He was inducted into the company in April 2018 as Chief Operating Officer before becoming CEO in July 2019. Mr. Israeli has an MBA from Bar-Ilan University, Israel, as well as over 30 years of experience. He had earlier worked at Enzymotec, where he was the President and CEO. Before that, he worked at Teva Pharmaceuticals for 23 years. He has held a multitude of positions, especially in the field of sales and marketing. G V Prasad, Co-chairman and MD Mr. Prasad was inducted into the company in 1990. He oversaw Dr. Reddy’s growth from a mid-sized domestic operation to a major global pharma brand today, with a presence in 66 countries and a valuation of billions of dollars. His core priority is on research, innovation, transparency, business ethics and leaner corporate structures. He also core priorityes on mentoring leaders driving innovation in science, technology and digitalisation.Corporate Actions
Bonus Shares Dr Reddy’s Laboratories had announced a bonus share in 2006 in the ratio of 1:1. Stock Splits Dr Reddy’s Laboratories had last split its shares from a face value of ₹10 to ₹5 in 2001. Dr Reddys Laboratories has not announced any rights issues or buyback of shares so far. Mergers and Acquisitions- In 2022-23, Dr. Reddy's Holdings Limited got merged with Dr Reddy's Laboratories Ltd. The merger became effective in April 2022.
- DRS LLC in Russia merged into Dr. Reddy's Laboratories LLC in July 2022.
- In 2017, Dr. Reddy's Laboratories completed the acquisition of a 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC), based out of Kolkata, for a consideration of ₹2.05 crore.
- In 2016, Dr. Reddy’s Laboratories gained complete control of 6 OTC brands from Ducere Pharma to enter the consumer health field.
- In 2002, the organization had made its first overseas acquisition in the form of BMS Laboratories Ltd. and Meridian Healthcare in the UK.
Financial Highlights
- The organization’s sales revenue has gone up by more than 100% in the period between March 2013 and March 2023.
- On the other hand, the organization’s net profits have increased by nearly 200% in the same period.
- The organization’s net cash flows have been volatile over the past years. From being in negative for the last few years, it increased to ₹1,286 crore in FY 2021, dropped to ₹3 in FY 2022 and further declined to -₹907 in FY 2023.
| Founded | : 1984 |
| Chairman | : K Satish Reddy |
| Managing Director | : G V Prasad |
| Address | : 8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034, |
| HO Tel | : 91-40-23731946 |
Open A Free Demat Account Today
Get StartedDocuments To Be Kept Handy
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)